Tech Company Financing Transactions
Sonoma Biotherapeutics Funding Round
Sonoma Biotherapeutics, based in San Francisco, scored $265 million from Ally Bridge Group, 8VC and Alexandria Venture Investments.
Transaction Overview
Company Name
Announced On
8/5/2021
Transaction Type
Venture Equity
Amount
$265,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
400 E. Jamie Ct. 250
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Overview
Best-in-class regulatory T cell therapy, delivering long-lasting, highly effective, curative treatments across a spectrum of autoimmune and degenerative diseases. Founded by pioneers in regulatory T cell therapy, Sonoma brings together next-generation research, development and manufacturing capabilities in cell therapy and genetic engineering.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jeffrey Bluestone
Chief Medical Officer
Leonard Dragone
Chief Scientific Officer
Fred Ramsdell
Vice President
James Adams
Vice President
Joshua Beilke
Vice President
Sejal Hall
VP - Bus. Development
Peter DiLaura
VP - Finance
Jillian McGuire
VP - Human Resources
Tamara Fountain
VP - Product Management
Anne-Renee Van Der Vuurst de Vries
VP - Product Management
Vanessa Van Voorhis
Browse more venture capital transactions:
Prev: 8/5/2021: Human Interest venture capital transaction
Next: 8/5/2021: Chronus venture capital transaction
Share this article
Where The Data Comes From
We report on funding rounds that are announced publicly. VC transactions on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs